Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation

Hepatology

Volumn 55, Issue 3, 2012, Pages 685-694

  Lütgehetmann, Marc ^a   Mancke, Lida V ^a   Volz, Tassilo ^a   Helbig, Martina ^a   Allweiss, Lena ^a   Bornscheuer, Till ^a   Pollok, Joerg M ^a   Lohse, Ansgar W ^a   Petersen, J ^b   Urban, Stephan ^c   Dandri, Maura ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LIPOPEPTIDE; MYRCLUDEX B; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; DELTA AGENT HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; IN VIVO STUDY; LIVER CELL; MIXED INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; STAINING; VIREMIA; VIRUS ENVELOPE; VIRUS INTERFERENCE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CHIMERA; COINFECTION; COMORBIDITY; DISEASE MODELS, ANIMAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS D; HEPATITIS DELTA ANTIGENS; HEPATITIS DELTA VIRUS; HEPATOCYTES; HUMANS; LIPOPEPTIDES; MICE; MICE, SCID; MICE, TRANSGENIC; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VIRUS REPLICATION;

EID: 84857442747     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24758     Document Type: Article

References (29)

1. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50: 1043-1050.
2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
3. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-1638.
4. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378: 73-85.
5. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. HEPATOLOGY 2006; 43: 750-760.
6. Sureau C. The role of the HBV envelope proteins in the HDV replication cycle. Curr Top Microbiol Immunol 2006; 307: 113-131.
7. Sureau C. The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model. Methods Mol Biol 2010; 640: 463-473.
8. Taylor JM. Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol 2006; 307: 1-23.
9. Taylor JM. Hepatitis delta virus. Virology 2006; 344: 71-76.
10. Casey JL. RNA editing in hepatitis delta virus genotype III requires a branched double-hairpin RNA structure. J Virol 2002; 76: 7385-7397.
11. Wong SK, Lazinski DW. Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1. Proc Natl Acad Sci U S A 2002; 99: 15118-15123.
12. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592.
13. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. HEPATOLOGY 2001; 34: 404-410.
14. Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol 2011; 85: 432-439.
15. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 2009; 90: 2759-2767.
16. Casey JL, Gerin JL. The woodchuck model of HDV infection. Curr Top Microbiol Immunol 2006; 307: 211-225.
17. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007; 13: 22-38.
18. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613-1622.
19. Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 2010; 84: 1989-2000.
20. Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsacker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341.
21. Dandri M, Murray JM, Lütgehetmann M, Volz T, Lohse AW, Petersen J. Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. HEPATOLOGY 2008; 48: 1079-1086.
22. Dandri M, Burda MR, Gocht A, Torok E, Pollok JM, Rogler CE, et al. Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. HEPATOLOGY 2001; 34: 824-833.
23. Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022-2029.
24. Volz T, Lütgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843-852.
25. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52: 658-664.
26. Dandri M, Petersen J. Chimeric mouse model of hepatitis B virus infection. J Hepatol 2011 July 27. [Epub ahead of print].
27. Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, et al. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011; 140: 2074-2083.
28. Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol 2003; 69: 313-323.
29. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331.